U.S. Online Retail and Ecommerce Stock News

Zai Lab (NasdaqGM:ZLAB) closed out FY 2025 with fourth quarter revenue of US$127.6 million and a basic EPS loss of US$0.46. Trailing 12 month figures show revenue of US$460.2 million and a basic EPS loss of US$1.60. Over recent periods the company has seen revenue range from US$102.3 million in Q3 2024 to US$127.6 million in Q4 2025, with quarterly basic EPS losses moving between US$0.33 and US$0.80. This sets up a picture where scale is building but margins are still under pressure for...

TPG (TPG) stock has come under pressure after investors focused on its £44 million exposure to failed UK mortgage lender Market Financial Solutions, which faces a reported £930 million collateral shortfall. See our latest analysis for TPG. The £44 million exposure to Market Financial Solutions comes on top of other recent headlines for TPG, including its role in a US$450 million Xerox joint venture financing and interest in the MarineMax sale process. Despite those developments, the share...

Alta Equipment Group (ALTG) has reported fourth quarter FY 2025 revenue of US$509.1 million with a basic EPS loss of US$0.39, setting the tone for a year where the business stayed focused on scale while earnings remained in the red. The company has seen quarterly revenue move from US$448.8 million in Q3 2024 to US$498.1 million in Q4 2024, then to US$423.0 million in Q1 2025 and up to US$509.1 million in Q4 2025, while basic EPS over that stretch ranged from a loss of US$0.34 to a loss of...

TeraWulf (WULF) closed FY 2025 with Q4 revenue of US$35.8 million and a basic EPS loss of US$0.30, alongside a trailing twelve month revenue base of US$168.5 million and a full year EPS loss of US$1.66. Over the last six reported quarters, revenue has ranged from US$27.1 million in Q3 2024 to US$50.6 million in Q3 2025, while quarterly basic EPS losses have moved between US$0.05 and US$1.13. This gives investors a clear picture of a business still working through heavy losses. With trailing...

Why MGIC Investment (MTG) Is On Investors’ Radar Today MGIC Investment (MTG) is drawing attention after recent trading left the mortgage insurer’s shares roughly flat over the past month, with a modest loss over the past 3 months and a decline year to date. See our latest analysis for MGIC Investment. At a share price of US$26.53, MGIC Investment’s short term share price return over the past 90 days has been negative, while its 1 year and 5 year total shareholder returns remain firmly...

Hudson Pacific Properties (HPP) closed out FY 2025 with Q4 revenue of US$256.0 million and basic EPS of US$4.31 loss, while trailing twelve month revenue came in at US$831.1 million alongside a TTM basic EPS of US$12.81 loss. This gives investors a clear snapshot of pressure on per share results. Over recent periods, the company has seen quarterly revenue shift from US$208.8 million in Q4 2024 to US$256.0 million in Q4 2025, with basic EPS moving from a loss of US$8.28 per share to a loss of...

Delek US Holdings (DK) closed out FY 2025 with Q4 revenue of US$2,429.4 million and basic EPS of US$1.32, alongside net income from continuing operations of US$79.5 million. Over the past few quarters, revenue has moved between US$2,641.9 million and US$2,887 million while basic EPS has swung from a loss of US$2.78 in Q1 2025 to a profit of US$2.96 in Q3 2025 and then US$1.32 in Q4, highlighting the sensitivity of margins to refining conditions and product mix. See our full analysis for Delek...

C4 Therapeutics (CCCC) just posted its FY 2025 Q4 numbers, with revenue of US$11.0 million and a quarterly loss translating to basic EPS of US$0.18, set against a trailing twelve month loss of US$105.0 million and EPS of US$1.27 on revenue of US$35.9 million. Over recent quarters, the company has seen revenue move between US$5.2 million and US$15.4 million, while quarterly EPS has ranged from US$0.35 to US$0.49 and quarterly losses from US$24.7 million to US$34.6 million. The key question for...

Cigna Group (CI) has wrapped up FY 2025 with fourth quarter revenue of US$72.5b, basic EPS of US$4.67 and net income of US$1,234m, putting a clear spotlight on how the year’s strong headline numbers translate into underlying profitability. The company has seen quarterly revenue move from US$65.6b in Q4 2024 to US$72.5b in Q4 2025, with basic EPS shifting from US$5.13 to US$4.67 over the same period. Trailing 12 month EPS reached US$22.33 on net income of US$5,957m, highlighting a year in...

Golden Entertainment (GDEN) has wrapped up FY 2025 with Q4 revenue of US$155.6 million and a basic EPS loss of US$0.33, alongside net income excluding extra items of a US$8.5 million loss. Over recent periods, the company has seen quarterly revenue move between US$154.8 million and US$164.2 million, while EPS has swung from a profit of US$0.18 in Q3 2024 to a loss of US$0.33 in Q4 2025. This leaves investors watching how quickly margins can stabilize from here. See our full analysis for...

Castle Biosciences (CSTL) has wrapped up FY 2025 with Q4 revenue of US$87 million and a basic EPS loss of US$0.08, alongside trailing twelve month revenue of US$344.2 million and a basic EPS loss of US$0.83. Over recent periods, the company has seen quarterly revenue range from US$83 million to US$88 million, while basic EPS has moved between a loss of US$0.90 and a profit of US$0.16. This sets the stage for investors to focus closely on how those revenue levels translate into sustainable...

What the latest earnings mean for W.W. Grainger (GWW) investors W.W. Grainger (GWW) recently posted quarterly results that topped expectations on both earnings and revenue, while management laid out full year guidance that points to higher projected EPS and sales compared with its latest reported figures. See our latest analysis for W.W. Grainger. At a share price of $1,144.73, W.W. Grainger has seen a 20.67% 90 day share price return and a 68.51% three year total shareholder return,...

FIGS (FIGS) closed out FY 2025 with Q4 revenue of US$201.9 million and basic EPS of US$0.11, while trailing twelve month EPS sat at US$0.21 on US$631.1 million of revenue. This came alongside a very large year over year earnings increase and a trailing net profit margin of 5.4% versus 0.5% a year earlier. The company has seen quarterly revenue move from US$151.8 million and EPS of US$0.01 in Q4 2024 to US$201.9 million and EPS of US$0.11 in Q4 2025, putting improving profitability front and...

Walker & Dunlop FY 2025 earnings snapshot Walker & Dunlop (WD) closed out FY 2025 with Q4 revenue of US$320.9 million and a basic EPS loss of US$0.39, as net income excluding extra items came in at a loss of US$13.1 million. The company reported quarterly revenue of US$321.0 million and EPS of US$1.32 in Q4 2024, compared with US$320.9 million and an EPS loss of US$0.39 in Q4 2025. Trailing twelve month revenue was US$1.2 billion and basic EPS was US$1.71. With margins under pressure and a...

Alignment Healthcare (ALHC) has wrapped up FY 2025 with Q4 revenue of US$1.0b and a basic EPS loss of US$0.05, alongside trailing 12 month revenue of US$4.0b and a near breakeven basic EPS of US$0.00. The company has seen quarterly revenue move from US$701.2m and a basic EPS loss of US$0.16 in Q4 2024 to US$1.0b and a basic EPS loss of US$0.05 in Q4 2025, while trailing 12 month basic EPS shifted from a loss of US$0.67 in Q4 2024 to a small loss of US$0.00 in Q4 2025, putting the focus firmly...

Cytek Biosciences (CTKB) closed out FY 2025 with Q4 revenue of US$62.1 million and a basic EPS loss of US$0.34, as net income excluding extra items came in at a loss of US$44.1 million. The company has seen quarterly revenue range from US$41.5 million to US$62.1 million over the past year, while basic EPS moved from a profit of US$0.07 in Q4 2024 to a loss of US$0.34 in Q4 2025. This shift highlights a clear pressure point on profitability. For investors, the latest print keeps the focus...

Riot Platforms reported revenues that exceeded consensus estimates. The company delivered an earnings surprise relative to market expectations. The results highlight operational performance that goes beyond price driven speculation. Riot Platforms, trading under NasdaqCM:RIOT, is drawing attention after its latest results, with revenue and earnings both coming in ahead of what the market had been expecting. The stock closed at $16.29, with a return of 15.0% year to date and 75.5% over the...

TriMas (TRS) has wrapped up FY 2025 with fourth quarter revenue of US$155.5 million and basic EPS of US$1.84, while trailing twelve month EPS stands at US$1.79 on revenue of US$645.7 million and a net profit margin of 11.2% versus 2.6% a year earlier. Over recent periods, the company has seen quarterly revenue range from US$228.1 million in Q4 2024 to US$274.8 million in Q2 2025, with basic EPS moving from US$0.14 in Q4 2024 to US$0.41 in Q2 2025 and US$0.31 in Q1 2025. With earnings over the...

Xponential Fitness (XPOF) just wrapped up FY 2025 with Q4 revenue of US$83.0 million, a basic EPS loss of US$0.93 and net income excluding extra items showing a loss of US$32.9 million. Over the past six quarters, the company has seen quarterly revenue move between US$76.2 million and US$83.8 million, while basic EPS ranged from a loss of US$0.01 to a loss of US$1.37. Trailing twelve month EPS stands at a loss of US$1.11 on revenue of US$314.9 million and a net loss excluding extra items of...

Rocket Lab (RKLB) has just put fresh numbers on the table for FY 2025, reporting Q4 revenue of US$179.7 million and a basic EPS loss of US$0.09, alongside trailing 12 month revenue of US$601.8 million and a full year EPS loss of US$0.37. The company’s quarterly revenue moved from US$132.4 million in Q4 2024 to US$179.7 million in Q4 2025, while quarterly EPS losses ranged between US$0.10 and US$0.13 across FY 2025. As a result, the focus for investors is on how quickly those losses can be...

Investors may be wondering whether Ocular Therapeutix at US$8.94 is starting to look interesting on price, or if the recent moves are already baking in the upside. The stock has been volatile lately, with a 14.9% gain over the last 7 days, a 13.0% decline over 30 days, a 24.4% decline year to date, a 25.2% return over 1 year, and 51.3% over 3 years, while still sitting 51.7% lower over 5 years. These swings have kept Ocular Therapeutix on the radar of investors watching for changing...

ICF International (ICFI) closed out FY 2025 with Q4 revenue of US$443.7 million and basic EPS of US$0.95, alongside trailing twelve month revenue of about US$1.9 billion and EPS of US$5.0 that frame the latest print against a full year backdrop. Over recent quarters, the company has seen revenue move from US$516.9 million in Q3 2024 to US$487.6 million in Q1 2025 and US$443.7 million in Q4 2025, while basic EPS shifted from US$1.74 to US$1.45 and then to US$0.95. This sets up a results season...

Globalstar (GSAT) has released its FY 2025 numbers, reporting Q4 revenue of US$72 million and a basic EPS loss of US$0.11. On a trailing twelve month basis, revenue came in at US$273 million and basic EPS was a loss of US$0.15. Over recent periods, the company has seen quarterly revenue range from US$60 million to US$74 million and basic EPS swing between a profit of US$0.13 and losses of up to US$0.42. This gives a clear view of how volatile margins have been as the business works through...

Concentra Group Holdings Parent FY 2025 earnings snapshot Concentra Group Holdings Parent (CON) has wrapped up FY 2025 with Q4 revenue of US$539.1 million and basic EPS of US$0.28, capping off a year where trailing 12 month revenue reached about US$2.2 billion and EPS sat at US$1.30. The company has seen quarterly revenue move from US$465.0 million in Q4 2024 to US$539.1 million in Q4 2025, while basic EPS over that same Q4 stretch shifted from US$0.17 to US$0.28, setting up a situation where...